Australia’s Recce Pharmaceuticals has announced positive data from a Phase II trial evaluating RECCE 327 Topical Gel (R327G) ...

Recce Pharma announces positive clinical data from phase II trial of RECCE 327 gel in acute bacterial skin & skin structure infections: Sydney Friday, February 21, 2025, 16:00 Hrs ...

The Phase II trial saw Recce 327 achieving all primary and secondary endpoints as the company looks to launch a Phase III trial.

UroGen Pharma has broadened its oncology pipeline by acquiring IconOVir Bio’s assets related to the oncolytic virus ICVB-1042.

ANI Pharmaceuticals offers an asymmetric opportunity in small-cap pharma, with a niche in generics, rare disease treatments, ...

Recce Pharmaceuticals’ synthetic gel successfully treated a range of skin infections in a phase 2 trial, leading the ...

D. Boral Capital reiterated their buy rating on shares of UroGen Pharma (NASDAQ:URGN – Free Report) in a report released on Tuesday morning,Benzinga reports. D. Boral Capital currently has a $25.00 ...

Allied Market Research published a report, titled, "Cell Culture Hydrogel Market By Type of Hydrogel (Natural Hydrogels, Synthetic Hydrogels, Hybrid Hydrogels), By Application (Cancer and Stem Cell ...

AlgoTherapeutix blames a “strong placebo effect” for the mid-stage failure for its pain gel ATX01, but the company still ...

Sonoma Pharmaceuticals (NASDAQ:SNOA – Get Free Report) will likely be posting its quarterly earnings results before the ...

Recce Pharmaceuticals Ltd has received positive findings from a Phase II clinical trial evaluating RECCE® 327 Topical Gel (R327G) for Acute Bacterial Skin and Skin Structure Infections (ABSSSI), ...